Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.67 USD
Change Today -0.02 / -0.54%
Volume 4.4K
RTTR On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

ritter pharmaceuticals inc (RTTR) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/24/15 - $5.50
52 Week Low
07/22/15 - $3.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ritter pharmaceuticals inc (RTTR) Related Businessweek News

No Related Businessweek News Found

ritter pharmaceuticals inc (RTTR) Details

Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal, and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. RP-G28 has been studied in a Phase 2a clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

5 Employees
Last Reported Date: 06/26/15
Founded in 2004

ritter pharmaceuticals inc (RTTR) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $90.0K
Founder, President and Director
Total Annual Compensation: $204.1K
Executive Chairman and Chief Strategic Office...
Total Annual Compensation: $182.9K
Compensation as of Fiscal Year 2014.

ritter pharmaceuticals inc (RTTR) Key Developments

Ritter Pharmaceuticals, Inc. Files Amended and Restated Certificate of Incorporation

On June 29, 2015, Ritter Pharmaceuticals, Inc. filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware in connection with the closing of the company's IPO. As described in the Registration Statement, the Company's board of directors and stockholders previously approved the Restated Certificate to be effective upon the closing of the company's IPO.

Ritter Pharmaceuticals, Inc.(NasdaqCM:RTTR) added to NASDAQ Composite Index

Ritter Pharmaceuticals, Inc. has been added to Nasdaq Composite Index.

Ritter Pharmaceuticals, Inc. Appoints Gerald T. Proehl to its Board of Directors

Ritter Pharmaceuticals, Inc. announced that Gerald T. Proehl has joined the Company’s Board of Directors. With his appointment, the Ritter Pharma Board now has seven Directors. Mr. Proehl will chair the Company’s nominating and corporate governance committee. Mr. Proehl served as President, Chief Executive Officer and Director of Santarus, Inc. from 2002 through the company’s acquisition in January 2014 by Salix Pharmaceuticals, Inc. for $2.6 billion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RTTR:US $3.67 USD -0.02

RTTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RTTR.
View Industry Companies

Industry Analysis


Industry Average

Valuation RTTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RITTER PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at